Hip implant manufacturers in the UK appeal NICE (National Institute for Clinical Excellence) ruling
This article was originally published in Clinica
Hip implant manufacturers in the UK have launched an appeal against draft recommendations on the clinical and cost effectiveness of their products by the National Institute for Clinical Excellence (NICE).
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.
An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.